A new anticancer drug has been successfully tested in Chongqing. It is a boron drug for BNCT boron neutron capture therapy, which can be used for malignant tumors, such as melanoma, brain cancer and glioma. BNCT anticancer boron drugs are still blank in China. If research and development is successful, it can be listed in 223. BNCT therapy uses boron compounds with strong affinity for cancer cells and neutron rays to kill cancer cells.
Inject boron compounds into patients, so that the boron compounds can gather in the focus of cancer cells, and then irradiate the affected areas with high-temperature neutron rays. After neutron rays come into contact with boron compounds, there will be a strong nuclear reaction. Neutrons have a short range and can kill cancer cells without damaging surrounding tissues. Boron is a rare nonmetallic substance. Medicinal boron-containing compounds have strong affinity with cancer cells. After being injected into patients, they will quickly gather with cancer cells to form cancer cell markers.
Neutrons are highly sensitive to boron, and will have a violent nuclear fission reaction with boron in cancer cells, releasing high energy? Radiation kills cancer cells. These drugs first patrol the body and hang targets on the doors of all cancer cells, so that the police can identify and kill cancer cells later. The medicine used in medical examination can emit red fluorescence, and the degree of boron absorption by cancer cells can be judged in advance through images, which is not only convenient for doctors to adjust flexibly, but also more reassuring for patients.
conventional radiotherapy can only kill oxygen-rich cells, while the remaining hypoxic cells or static cells are harmful to conventional X-ray, X-ray and X-ray. Radiation and electron beam are sensitive and highly resistant, which is also the reason why cancer is easy to recur after routine treatment. Neutron rays have a special effect on hypoxic cells. The recovery rate of hypoxic cells greatly reduces the possibility of cancer recurrence. This hypoxic cancer cell is particularly sensitive to neutron rays. The reactivation rate of hypoxic cells in tumor site is almost zero, and the postoperative tumor recurrence rate is very low, which is the unique advantage of neutron therapy.